Selected article for: "acute respiratory syndrome and lung protective"
Author: Buckley, Leo F.; Cheng, Judy W. M.; Desai, Akshay
Title: Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2
  • Cord-id: mfqlv3nh
  • Document date: 2020_4_13
    • ID: mfqlv3nh
    Snippet: Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (ACE2). Preclinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. In addition, renin–angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure, and chronic
    Document: Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (ACE2). Preclinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. In addition, renin–angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology, as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin–angiotensin–aldosterone system inhibitor therapy.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • ace inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace inhibitor and lung damage: 1
    • ace inhibitor and lung function: 1, 2
    • ace inhibitor discontinue and acute respiratory: 1
    • ace inhibitor discontinue and acute respiratory syndrome: 1
    • ace inhibitor receive and acute respiratory: 1
    • ace inhibitor receive and acute respiratory distress syndrome: 1
    • ace inhibitor receive and acute respiratory syndrome: 1
    • ace inhibitor therapy and acute respiratory: 1, 2, 3, 4, 5
    • ace inhibitor therapy and acute respiratory distress syndrome: 1, 2
    • ace inhibitor therapy and acute respiratory syndrome: 1, 2, 3, 4
    • ace inhibitor therapy and lung function: 1
    • ace inhibitor treatment and acute respiratory: 1, 2, 3, 4, 5
    • ace inhibitor treatment and acute respiratory syndrome: 1, 2, 3, 4
    • acid aspiration and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acid aspiration and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acid aspiration and acute respiratory distress syndrome patient: 1, 2